NCT00477035View on ClinicalTrials.gov

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
LeukemiaMultiple Myeloma
Interventions
DRUG

CIK cells

2x10e8 cells/kg

DRUG

etoposide

60 mg/kg

DRUG

bcnu

15 mg/kg

DRUG

cyclophosphamide

100 mg/kg

DRUG

gemcitabine

1250 mg/m2

DRUG

vinorelbine

30 mg/m2

DRUG

melphalan

200 mg/m2

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Sally Arai

OTHER

NCT00477035 - Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | Biotech Hunter | Biotech Hunter